Therapeutic hypothermia-induced pharmacokinetic alterations on CYP2E1 chlorzoxazone-mediated metabolism in a cardiac arrest rat model

Critical Care Medicine

Volumn 34, Issue 3, 2006, Pages 785-791

  Tortorici, Michael A ^a   Kochanek, Patrick M ^b,c   Bies, Robert R ^a   Poloyac, Samuel M ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Cardiac arrest; Chlorzoxazone; CYP2E1; Drug metabolism; Hypothermia; Pharmacokinetics

Indexed keywords

CHLORZOXAZONE; CYTOCHROME P450 2E1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPHYXIA; CONTROLLED STUDY; COOLING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME KINETICS; ENZYME METABOLISM; ENZYME SUBSTRATE; HEART ARREST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INCUBATION TIME; INDUCED HYPOTHERMIA; LIVER MICROSOME METABOLISM; MALE; MICHAELIS CONSTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; SPECIES COMPARISON;

ANALYSIS OF VARIANCE; ANIMALS; AREA UNDER CURVE; CHLORZOXAZONE; CYTOCHROME P-450 CYP2E1; HEART ARREST; HYPOTHERMIA, INDUCED; MALE; METABOLIC CLEARANCE RATE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33644607442     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000201899.52739.4F     Document Type: Article

References (36)

1. Rea TD, Pearce RM, Raghunathan TE, et al: Incidence of out-of-hospital cardiac arrest. Am J Cardiol 2004; 93:1455-1460
2. Negovsky VA: Postresuscitation disease. Crit Care Med 1988; 16:942-946
3. Laver S, Farrow C, Turner D, et al: Mode of death after admission to an intensive care unit following cardiac arrest. Intensive Care Med 2004; 30:2126-2128
4. Bernard SA, Gray TW, Buist MD, et al: Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002; 346:557-563
5. Holzer M, Cerchiari E, Martens P, et al: Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002; 346:549-556
6. Nolan JP, Morley PT, Hoek TL, et al: Therapeutic hypothermia after cardiac arrest. An advisory statement by the Advancement Life Support Task Force of the International Liaison Committee on Resuscitation. Resuscitation 2003; 57:231-235
7. Bertz RJ, Granneman GR: Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32:210-258
8. Caldwell JE, Heier T, Wright PM, et al: Temperature-dependent pharmacokinetics and pharmacodynamics of vecuronium. Anesthesiology 2000; 92:84-93
9. Koren G, Barker C, Bohn D, et al: Influence of hypothermia on the pharmacokinetics of gentamicin and theophylline in piglets. Crit Care Med 1985; 13:844-847
10. Koren G, Barker C, Goresky G, et al: The influence of hypothermia on the disposition of fentanyl - Human and animal studies. Eur J Clin Pharmacol 1987; 32:373-376
11. Fukuoka N, Aibiki M, Tsukamoto T, et al: Biphasic concentration change during continuous midazolam administration in brain-injured patients undergoing therapeutic moderate hypothermia. Resuscitation 2004; 60:225-230
12. Leslie K, Sessler DI, Bjorksten AR, et al: Mild hypothermia alters propofol pharmacokinetics and increases the duration of action of atracurium. Anesth Analg 1995; 80: 1007-1014
13. Iida Y, Nishi S, Asada A: Effect of mild therapeutic hypothermia on phenytoin pharmacokinetics. Ther Drug Monit 2001; 23: 192-197
14. Lieber CS: Cytochrome P-4502E1: Its physiological and pathological role. Physiol Rev 1997; 77:517-544
15. Fink EL, Alexander H, Marco CD, et al: Experimental model of pediatric asphyxial cardiopulmonary arrest in rats. Pediatr Crit Care Med 2004; 5:139-144
16. Rockich K, Blouin R: Effect of the acute-phase response on the pharmacokinetics of chlorzoxazone and cytochrome P-450 2E1 in vitro activity in rats. Drug Metab Dispos 1999; 27:1074-1077
17. Tong V, Abbott FS, Mbofana S, et al: In vitro investigation of the hepatic extraction of RSD1070, a novel antiarrhythmic compound. J Pharm Pharm Sci 2001; 4:15-23
18. Bachmann K, Sarver JG: Chlorzoxazone as a single sample probe of hepatic CYP2E1 activity in humans. Pharmacology 1996; 52: 169-177
19. Cullen DJ, Sweitzer BJ, Bates DW, et al: Preventable adverse drug events in hospitalized patients: A comparative study of intensive care and general care units. Crit Care Med 1997; 25:1289-1297
20. Michelsen LG, Holford NH, Lu W, et al: The pharmacokinetics of remifentanil in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Anesth Analg 2001; 93:1100-1105
21. Statler KD, Alexander HL, Vagni VA, et al: Moderate hypothermia may be detrimental after traumatic brain injury in fentanylanesthetized rats. Crit Care Med 2003; 31: 1134-1139
22. Heier T, Caldwell JE, Sessler DI, et al: Mild intraoperative hypothermia increases duration of action and spontaneous recovery of vecuronium blockade during nitrous oxideisoflurane anesthesia in humans. Anesthesiology 1991; 74:815-819
23. Kofke WA, Garman RH, Garman R, et al: Opioid neurotoxicity: Fentanyl-induced exacerbation of cerebral ischemia in rats. Brain Res 1999; 818:326-334
24. Heier T, Caldwell JE, Sharma ML, et al: Mild intraoperative hypothermia does not change the pharmacodynamics (concentration-effect relationship) of vecuronium in humans. Anesth Analg 1994; 78:973-977
25. Pang KS, Rowland M: Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 1977; 5:625-653
26. Pang KS, Rowland M: Hepatic clearance of drugs. II. Experimental evidence for acceptance of the "well-stirred" model over the "parallel tube" model using lidocaine in the perfused rat liver in situ preparation. J Pharmacokinet Biopharm 1977; 5:655-680
27. Pang KS, Rowland M: Hepatic clearance of drugs. III. Additional experimental evidence supporting the "well-stirred" model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liver in situ preparation. J Pharmacokinet Biopharm 1977; 5:681-699
28. Tanaka E: Chlorzoxazone: A probe drug the metabolism of which can be used to monitor one-point blood sampling in the carbon tetrachloride-intoxicated rat. Hum Exp Toxicol 2001; 20:381-385
29. McAllister RG Jr, Tan TG: Effect of hypothermia on drug metabolism. In vitro studies with propranolol and verapamil. Pharmacology 1980; 20:95-100
30. Obach RS, Baxter JG, Liston TE, et al: The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283:46-58
31. Khatsenko O: Interactions between nitric oxide and cytochrome P-450 in the liver. Biochemistry (Mosc) 1998; 63:833-839
32. Abdel-Razzak Z, Loyer P, Fautrel A, et al: Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993; 44:707-715
33. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: Advanced cardiovascular life support: Section 8: Postresuscitation care. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 2000; 102(8 Suppl): I166-I171
34. Adrie C, Adib-Conquy M, Laurent I, et al: Successful cardiopulmonary resuscitation after cardiac arrest as a "sepsis-like" syndrome. Circulation 2002; 106:562-568
35. Qi WN, Chaiyakit P, Cai Y, et al: NF-kappaB p65 involves in reperfusion injury and iNOS gene regulation in skeletal muscle. Microsurgery 2004; 24:316-323
36. Tateishi T, Watanabe M, Nakura H, et al: Halothane inhalation inhibits the metabolism of chlorzoxazone, a substrate for CYP2E1, in rabbits. Anesth Analg 1997; 85: 199-203